ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
SOUTH SAN FRANCISCO, Calif., July 26, 2017 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on July 24, 2017, the compensation committee of the Company’s board of directors granted one new employee an option to purchase 30,000 shares of the Company’s common stock with a per share exercise price of $30.25, the closing trading price on the grant date, and a restricted stock unit award for 25,000 shares of the Company’s common stock, in each case under the Company’s 2017 Inducement Equity Plan (the “Plan”).
The above-described awards were each granted as an inducement material to the employee’s entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Company has reserved an aggregate of 300,000 shares of its common stock (including the shares underlying the stock option and restricted stock unit award described above) for issuance under the Plan, which was approved by the Company’s Board of Directors in January 2017.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in two ongoing Phase 2a studies in patients with idiopathic pulmonary fibrosis. To learn more, please visit www.globalbloodtx.com and follow the company on Twitter: @GBT_news.
Contact Information: Myesha Lacy (investors) GBT 650-351-4730 [email protected] Joey Fleury (media) Pure Communications 415-946-1090 [email protected]
